The presence of CCR7 alterations was associated with shorter survival among patients with adult T-cell leukemia/lymphoma (ATL) treated with mogamulizumab without allogeneic hematopoietic stem cell transplantation (HSCT), according to a cohort study published in the journal Hematological Oncology.

A previous study suggested that CCR7 alterations were associated with clinical response to mogamulizumab. The purpose of this study was to evaluate this potential association in a larger cohort.

This prospective study evaluated data from 223 patients with ATL. CCR7 and other gene alterations were identified using DNA sequencing. The choice of treatment for each patient was decided by the clinical investigator. The median age of the cohort was 66.5 and the majority of patients had an acute subtype of ATL.


Continue Reading

CCR7 alterations were identified among 12% of patients, which primarily caused C-terminus truncation in the protein, and were more common among women (17%) compared with men (8%; P =.063). Additional gene alterations included TP53 among 41% of patients, CD28 among 37%, and CCR4 among 31%. Co-occurring alterations in CCR4, CD28, and TP53 were present among 26%, 33%, and 59% of patients, respectively, with CCR7 alterations.

CC47 alterations was not associated with clinical outcome in the entire cohort of patients with ATL or among patients who underwent HSCT. However, among patients treated with mogamulizumab without HSCT, shorter survival was significantly associated with CCR7 alterations with a median of 0.7 years compared with 1.6 years without CCR7 alterations (P =.020).

In a multivariate analysis, shorter survival was associated with an alteration in TP53 (hazard ratio [HR], 2.685; 95% CI, 1.427-5.050; P =.002), whereas longer survival as significantly associated with CCR4 alterations in the absence of CCR7 alterations (HR, 0.437; 95% CI, 0.192-0.994; P =.048).

The authors concluded that “the presence or absence of CCR7 alterations, especially in combination with CCR4 alterations, is a valuable biomarker to predict the clinical outcome of mogamulizumab-containing treatments in ATL.”

Disclosures: Some of the study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.

Reference

Sakamoto Y, Ishida T, Masaki A, et al. CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Hematol Oncol. Published online August 31, 2022. doi: 10.1002/hon.3072